** Hong Kong shares of WuXi AppTec fall as much as 20.6% to HK$45, their lowest since Feb 21
** Stock last down 11.9%; second biggest pct loser in Hang Seng Index and Hang Seng Composite Index
** Shanghai shares opens down a maximum 10%
** The U.S. Senate's homeland security committee voted on Wednesday to approve a bill that could restrict business with Chinese biotech companies like BGI and WuXi AppTec on national security grounds
** The bill is designed to keep Americans' personal health and genetic information from foreign adversaries
** The bill has spurred deep concern among investors, driving a sell-off in the shares of WuXi AppTec when news of its introduction first reached Chinese markets last month
** Shares of WuXi Biologics , an affilate of WuXi AppTec, fall as much as 18.9% to HK$17.64, lowest since Feb 21
** Stock of WuXi XDC , a unit of WuXi Biologics, drop 18.8% to HK$18.84, lowest since March 1
** Hong Kong's healthcare index falls 2.4%, while Hang Seng Composite Index and Hang Seng Index both slip 0.1%
** Hong Kong stock of WuXi AppTec drops 38.6% YTD, WuXi Biologics down 39.1% YTD, WuXi XDC down 36.7% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Comments